Clinical Trial

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 28, 2020 (before its estimated January 8, 2022 completion). Its status may not reflect the trial's current state.
Summary
A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2020-01-09; most recent amendment 2020-12-24.
Trial Details
NCT Number NCT04227015
Lead Sponsor He Huang
Collaborators: Nanjing Bioheng Biotech Co., Ltd.
Conditions Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma
Enrollment 72 participants
Start Date 2020-01-08
Primary Completion 2022-01-08 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2020-12-28